Taking it

The standard dose of abacavir (Ziagen) is one 300mg tablet twice a day, twelve hours apart, or once a day at a dose of 600mg. It can be taken with or without food. Abacavir is dosed once daily when combined with lamivudine in the tablet coformulation (Kivexa/Epzicom).

A strawberry- and banana-flavoured abacavir solution at a concentration of 20mg/ml is also available for use in children and adults who cannot take tablets. The oral solution of abacavir contains 340mg/l sorbitol. This means that the product is unsuitable for people with hereditary fructose intolerance. Sorbitol can also cause stomach upset and diarrhoea.

Abacavir is generally not recommended for people with cirrhosis or mild liver impairment because they are not able to process the drug properly and high drug levels occur. One study has recommended an abacavir dose of 150mg twice daily for people with liver damage, although there are no definitive recommendations on appropriate dose adjustments.1

Abacavir should not be taken by people with end-stage kidney disease.

As with all anti-HIV drugs, it is important to take the drug as prescribed in order to maintain the right level of the drug in the blood. If blood levels of the drug fall too low, this will help the development of resistance to abacavir and may affect future treatment options.

References

  1. Raffi F et al. Pharmacokinetics of, and tolerability to, a single, oral, 600 mg dosage of abacavir in HIV-positive subjects with or without liver disease. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, abstract 1630, 2000
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.